BMJ analysis: Optional copayments on anti-cancer drugs

Source: BMJ Area: News In this BMJ analysis, the authors note that "new cancer drugs are often expensive and offer low cost effectiveness, yet funders find it hard to resist the pressure to provide them to dying patients." They argue that because these drugs have only marginal efficacy it is reasonable to ask patients to contribute to their excess costs through optional copayments.   Their article covers the following topics:   . Example of bevacizumab and cetuximab . The regulatory game . General argument for copayments . Copayments and expensive cancer drugs . Effect on communication
Source: NeLM - News - Category: Drugs & Pharmacology Source Type: news